# A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Repaglinide and Caffeine

> **NCT02128321** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Pharmacokinetics of Repaglinide
- Pharmacokinetics of Caffeine
- Healthy Subjects

## Interventions

- **DRUG:** Isavuconazole
- **DRUG:** Repaglinide
- **DRUG:** Caffeine

## Key facts

- **NCT ID:** NCT02128321
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02128321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02128321, "A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Repaglinide and Caffeine". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02128321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*